- Home
- CRT vs MDCX Comparison
CRT vs MDCX Comparison
Compare CRT & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Company Overview
Basic Information| Metric | CRT | MDCX |
|---|---|---|
| Founded | 1991 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 45.2M |
| IPO Year | 1992 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRT | MDCX |
|---|---|---|
| Price | $8.61 | $2.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | 37.0K | ★ 332.0K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 8.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $5,621,913.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.62 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.07 | $1.68 |
| 52 Week High | $13.31 | $8.94 |
Technical Indicators
Market Signals| Indicator | CRT | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 56.23 | 47.11 |
| Support Level | $8.29 | $1.68 |
| Resistance Level | $8.99 | $2.26 |
| Average True Range (ATR) | 0.20 | 0.19 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 41.82 | 42.86 |
Price Performance
Historical Comparison CRT
MDCX
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.